Skip to main content
. Author manuscript; available in PMC: 2021 Sep 27.
Published in final edited form as: J Med Genet. 2019 Nov 29;57(5):331–338. doi: 10.1136/jmedgenet-2019-106283

Table 4.

False Positive Rates for Unbalanced Trials Over a Simulation of 2 Years

Year 1 Year 2
Sample Size Total N(%) of FP N(%) of FP by SNP Effect Total N(%) of FP N(%) of FP by SNP Effect
50 61 (6.1%) 30 (49.2%) 56 (5.6%) 40 (71.4%)
100 58 (5.8%) 48 (82.8%) 52 (5.2%) 44 (84.6%)
200 59 (5.9%) 43 (72.9%) 57 (5.7%) 49 (86.0%)
300 45 (4.5%) 32 (71.1%) 57 (5.7%) 47 (86.0%)
600 45 (4.5%) 32 (71.1%) 57 (5.7%) 43 (75.4%)
700 60 (6.0%) 47 (78.3%) 48 (4.8%) 44 (91.7%)
800 57 (5.7%) 43 (75.4%) 43 (4.3%) 32 (74.4%)

FP = false positive. False positive rates were investigated by determining the number of significant and non-significant trials when comparing change in UPDRS over a simulation of two years. Total % of false positives is the percentage of total iterations that resulted in a false positive. % of false positives by SNP effect is the percentage of false positives that were caused by the interaction effect on UPDRS progression by the rs9298897 and rs17710829 SNPs alone. Significance was determined by Z score cut-off values of ± 1.96 (p < 0.05).